Opinion

Video

Ongoing Research and Unmet Needs in Patients With Breast Cancer and ESR1 Mutations

Drs Mayer and Kalinsky conclude their discussion with a look at agents in development and unmet needs for patients with breast cancer and ESR1 mutations.

This is a synopsis of an Insights series featuring Kevin Kalinsky, MD, MS, of Winship Cancer Institute of Emory University, and Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute.

As the discussion concluded, Dr Erica Mayer highlighted several promising novel agents for hormone receptor-positive breast cancer beyond selective estrogen receptor degraders [SERDs]. These include proteolysis-targeting chimeras [PROTACs] like ARV-471 [vepdegestrant] and selective estrogen receptor covalent antagonists [SERCAs] like H3B-6527 which may more potently inhibit estrogen receptor signaling.

Early phase clinical data presented at recent conferences suggests meaningful single-agent activity from both investigational drug classes despite heavily pretreated populations, with manageable toxicity. Combinations also appear feasible, though some unique drug-drug interactions may require consideration, as Dr Kevin Kalinsky noted a PROTAC/CDK4/6 inhibitor regimen showed heightened neutropenia.

Dr Kalinsky was also intrigued by phase III results for the selective estrogen receptor modulator lasofoxifene from the ELAINE studies, which improved progression-free survival over endocrine options when combined with abemaciclib. The ongoing phase III ELAINE-3 trial is evaluating lasofoxifene plus abemaciclib compared with fulvestrant plus abemaciclib specifically in patients harboring ESR1 mutations who progressed on prior CDK4/6 blockade. Demonstrating efficacy in this post-CDK4/6 setting could support a differentiated approval.

In closing, Dr Mayer emphasized practical challenges to integrating comprehensive genomic profiling for targetable alterations like ESR1 mutations into real-world practice. Overcoming barriers to accessible, serial ctDNA testing is imperative to realize the full potential of emerging biomarker-driven breast cancer therapies. Drs Kalinsky and Mayer urge focused education and implementation efforts surrounding ctDNA analysis to evolve the standard of care.

*Video synopsis is AI-generated and reviewed by OncLive editorial staff.

Related Videos
Sheldon M. Feldman, MD
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.
In this episode of OncChats: Empowering Community Cancer Care, Dr. Woodworth sheds light on the “Road to Recovery” survivorship program at Henry Mayo, which supports cancer survivors by providing them with fitness, education, and mental health resources, and underscores the importance of mentorship programs for community providers to ensure equitable cancer care.
In this episode of OncChats: Empowering Community Cancer Care, Drs Woodworth and Rai, discuss their collaborative approach to cancer screening, emphasizing the importance of community efforts and individual assessments in integrating genetic testing and screenings into routine practice.